Using immunochemical analyses, Roger et al [31] found a higher percentage of ERβ positive cells in normal mammary glands than in non-proliferative benign breast disease (85%), proliferative disease without atypia (18.5%) and carcinoma in situ (33.8%). Here, ESR2 is linked to breast fibrocystic disease.